Pfizer buckles under pressure from Trump, delays drug price increases

Pfizer chief executive Ian Read said late Tuesday that his company would delay increasing the prices of dozens of drug products after President Trump publicly berated the firm one day earlier.

The company, in a statement, said the price increases would effectively be postponed at least until the beginning of 2019 “to give the president an opportunity to work on his blueprint to strengthen the healthcare system and provide more access to patients.”